Europska Unija - hrvatski - EMA (European Medicines Agency)

takeda manufacturing austria ag - c1 inhibitor (humani) - angioedemas, nasljedni - c1-inhibitor; u plazmi derivata, lijekova koji se koriste u потомственное angioedema - liječenje i pre-postupak prevencije angioedemskih napada u odraslih, adolescenata i djece (2 godine i više) s nasljednim angioedemom (hae). rutinski profilaksa angioedema, udara kod odraslih, djece i adolescenata (sa 6 godina); kod teških i рецидивирующих udara nasljedni ангионевротического edema (he), koji ne podnose ili nedovoljno zaštićeni usmeno upozorenje liječenje, ili u pacijenata koji su neadekvatno upravlja, kada se ponavljaju akutno liječenje.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

csl behring gmbh, emil-von-behring-str. 76, marburg, njemačka - inhibitor c1-esteraze, ljudski - prašak i otapalo za otopinu za injekciju - urbroj: jedna bočica sadrži 3000 iu inhibitora c1-esteraze, ljudskog; nakon rekonstitucije s 5,6 ml otapala vode za injekciju sadrži 500 iu/ml inhibitora c1-esteraze.

Europska Unija - hrvatski - EMA (European Medicines Agency)

pharming group n.v. - Рекомбинантный c1-inhibitor - angioedemas, nasljedni - drugs used in hereditary angioedema, other hematological agents - ruconest je indiciran za liječenje akutnih angioedemskih napada kod odraslih osoba s nasljednim angioedemom (hae) zbog nedostatka c1-estera-inhibitora.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

csl behring gmbh, emil-von-behring-str. 76, marburg, njemačka - inhibitor c1-esteraze, ljudski - prašak i otapalo za otopinu za injekciju - urbroj: jedna bočica sadrži 1500 iu ljudskog inhibitora c1-esteraze; nakon rekonstitucije s 3 ml otapala vode za injekciju sadrži 500 iu/ml ljudskog inhibitora c1-esteraze.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

csl behring gmbh, emil-von-behring-str. 76, marburg, njemačka - inhibitor c1-esteraze, ljudski - prašak i otapalo za otopinu za injekciju - urbroj: jedna bočica sadrži 2000 iu ljudskog inhibitora c1-esteraze; nakon rekonstitucije s 4 ml otapala vode za injekciju sadrži 500 iu/ml ljudskog inhibitora c1-esteraze.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

csl behring gmbh, emil-von-behring-str. 76, marburg, njemačka - inhibitor c1-esteraze, ljudski - prašak i otapalo za otopinu za injekciju / infuziju - urbroj: jedna bočica sadrži 500 iu ljudskog inhibitora c1-esteraze; nakon rekonstitucije s 10 ml otapala vode za injekciju sadrži 50 iu/ml ljudskog inhibitora c1-esteraze.

Europska Unija - hrvatski - EMA (European Medicines Agency)

takeda pharmaceuticals international ag - ikatiban - angioedemas, nasljedni - srčana terapija - firazyr je indiciran za simptomatsko liječenje akutnog napada nasljednog angioedema (hae) u odraslih osoba (sa c1 esteraze nedostatak).

Europska Unija - hrvatski - EMA (European Medicines Agency)

accord healthcare s.l.u. - icatibant acetate - angioedemas, nasljedni - other hematological agents - icatibant accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older, with c1 esterase inhibitor deficiency.

Europska Unija - hrvatski - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinuria, paroxysmal - imunosupresivi - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.

Europska Unija - hrvatski - EMA (European Medicines Agency)

sandoz gmbh - rituksimab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastična sredstva - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. postoje samo ograničeni podaci o učinkovitosti i sigurnosti bolesnika prethodno liječenih monoklonsko antitijelo, uključujući rituksimab ili bolesne, vatrostalne standardnim tretmanima na prethodnu rituksimab + kemoterapija. cm. odjeljak 5. 1 za daljnje informacije. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituksimab je pokazala da smanjuje brzinu progresije oštećenja zglobova kao što se mjeri x-ray i poboljšati fizičku funkciju, prilikom raspoređivanja u kombinaciji s metotreksatom. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).